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Abstract
Introduction Sepsis is associated with the generation of oxygen
free radicals and (lacking) decreased selenium plasma
concentrations. High doses of sodium selenite might reduce
inflammation by a direct pro-oxidative effect and may increase
antioxidant cell capacities by selenium incorporation into
selenoenzymes. We investigated the effects of a continuous
administration of high doses of selenium in septic shock
patients.
Methods A prospective, multicentre, placebo-controlled,
randomized, double-blind study was performed with an
intention-to-treat analysis in severe septic shock patients with
documented infection. Patients received, for 10 days, selenium
as sodium selenite (4,000 μg on the first day, 1,000 μg/day on
the nine following days) or matching placebo using continuous
intravenous infusion. The primary endpoint was the time to
vasopressor therapy withdrawal. The duration of mechanical
ventilation, the mortality rates in the intensive care unit, at
hospital discharge, and at 7, 14, 28 and 180 days and 1 year
after randomization, and adverse events were recorded.
Results Sixty patients were included (placebo, n  = 29;
selenium, n  = 31). The median time to vasopressor therapy
withdrawal was 7 days in both groups (95% confidence interval
= 5–8 and 6–9 in the placebo and selenium groups,
respectively; log-rank, P  = 0.713). The median duration of
mechanical ventilation was 14 days and 19 days in the placebo
and selenium groups, respectively (P = 0.762). Mortality rates
did not significantly differ between groups at any time point.
Rates of adverse events were similar in the two groups.
Conclusion Continuous infusion of selenium as sodium selenite
(4,000 μg on the first day, 1,000 μg/day on the nine following
days) had no obvious toxicity but did not improve the clinical
outcome in septic shock patients. Trial Registration =
NCT00207844.
Introduction
Septic shock – an uncontrolled systemic host response to
invasive infection leading to multiple organ failure – is a public
health issue because of its frequency, cost and 45% mortality
rate [1,2]. The physiopathology of septic shock is better
understood with increasing data supporting the key role of
FiO2 = fraction of inspired oxygen; ICU = intensive care unit; NF = nuclear factor; PaO2 = arterial partial pressure of oxygen; SOFA = Sequential 
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oxidant stress, especially on endothelium damage [3-5]. In
severe sepsis patients or in systemic inflammatory response
syndrome patients, there is an early 40% decrease in plasma
selenium concentrations that could be associated with a
decrease of antioxidant defences [6]. Recent data suggest
that selenium administration as sodium selenite could induce
a dose-dependent favourable effect on the clinical outcome
and survival in septic shock, especially in severe septic shock
patients [3,7-10].
Selenium can induce two fundamental types of effects: antioxi-
dant, through its incorporation into selenoenzymes; and pro-
oxidant, through the direct effects of selenocompounds.
Selenoenzymes, which require one atom of selenium at their
active site to be functional, protect cells against damages
related to oxidative stress [11,12]. Among them, selenoprotein
P may be involved in endothelium protection during sepsis
[13]. These ubiquitous enzymes regulate many intracellular
metabolic pathways such as arachidonic acid cascade, NF-κB
transcription activation, transcriptional activities and mitochon-
drial functions [14-17]. Owing to their numerous biological
functions, a severe selenium deficiency may be lethal [18].
In contrast, selenocompounds, especially sodium selenite, can
display pro-oxidant properties that may be toxic [19,20].
Indeed, selenium was initially known as a toxic element in ani-
mal poisoning by selenium-rich plants [21]. In animals, the min-
imum lethal dose for intravenous administration of sodium
selenite is between 1.5 and 3 mg/kg [22,23]. In humans, acute
lethal poisonings are rare [22-25], with observed toxic effects
clinically similar to those of arsenic [25]. The minimum lethal
dose seems to be similar to that for animals [22]. The toxicity
of selenium compounds, especially sodium selenite, is consid-
ered to be related to its pro-oxidant properties [19,20,26,27].
The daily nutritional intakes to avoid deleterious effects have
been established as 400 μg for the tolerable-upper-intake
level and as 800 μg for the no-adverse-event level [28],
whereas a unique ingestion of 4 mg selenium is considered
nontoxic in a healthy man [22]. In the case of oxidative stress
related to septic shock, administration of more than 700 μg/
day selenium is currently not recommended due to the pro-oxi-
dative effect of selonocompounds [23,29-31]. In clinical trials,
however, daily doses up to 1,000 μg have been repeatedly
used without detectable adverse effects [8,10].
In septic shock treatment, the pro-oxidant properties of
selenite may be interesting as they may temporarily reduce
excessive inflammation by inhibiting NF-κB to DNA binding
[32,33] or by inducing a proapoptotic effect on activated cir-
culating cells [13,20,34]. We therefore designed the present
study to assess the efficacy and safety of a continuous infu-
sion of sodium selenite initially given at a pro-oxidative high
dose, cautiously (lacking) administered continuously, followed
by an antioxidative lower dose in septic shock patients.
Methods
Study design
A prospective, placebo-controlled, randomized, double blind,
phase II study was conducted in seven centres in France. The
protocol was approved by the Consultative Committee for the
Protection of People in Biomedical Research (Comité Con-
sultatif de Protection des Personnes dans la Recherche
Biomédicale) of Saint-Germain en Laye, France on 15 March
2001.
Patients
Patients older than 18 years and hospitalized in participating
intensive care units (ICUs) were enrolled in the study if they
met the following criteria: severe documented infection, as evi-
denced by one or more of a positive culture or Gram stain of a
normally sterile body fluid, of a clinical patent focus of infection
(for example, faecal peritonitis, community pneumonia) and of
a nosocomial documented infection (for example, ventilation-
acquired nosocomial pneumonia or catheter-related infection);
a need for mechanical ventilation; severe septic shock, defined
as circulatory failure that required at least 1,000 ml fluid
replacement in the previous 24 hours and was treated for at
least 1 hour with more than 15 μg/kg/min dopamine or more
than 0.2 μg/kg/min epinephrine or norepinephrine corre-
sponding to class 4 of cardiovascular failure in the Sequential
Organ Failure Assessment (SOFA) score; a Simplified Acute
Physiologic Score II of 25 or more; and written informed con-
sent from the patients themselves or their representatives.
Patients were excluded if they were pregnant, if they had end-
phase chronic disease, if they had a medical staff decision of
limitation of care, if they had preliminary circulatory failure, if
they had shock due to a urinary infection without bacteraemia,
if they had peritonitis related to peritoneal dialysis or trauma, or
if they were participating in another clinical trial.
Treatments
Patients were randomly assigned in a 1:1 manner to receive
either sodium selenite or matching placebo for 10 days. Treat-
ments (Laboratoires Aguettant, Lyon, France) were condi-
tioned in ampoules containing 1 mg selenium as sodium
selenite diluted in 48 ml saline and were administered intrave-
nously by continuous infusion (2 ml/hour) at the following
doses, expressed in selenium content: 4,000 μg on the first
day and 1,000 μg/day on the nine following days. Randomiza-
tion was stratified on each centre by blocks of four. In each
centre, sequentially identical numbered boxes containing the
whole treatment for each patient were delivered to the investi-
gator by the pharmacist following the order of the randomiza-
tion list. All patients, medical and nursing staff, and
pharmacists remained blinded throughout the study period.Available online http://ccforum.com/content/11/4/R73
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Data collection at inclusion
Clinical variables
The following data were recorded at inclusion. First, the base-
line characteristics, the underlying condition assessed by the
McCabe score, the length of hospital stay and the time in the
ICU before enrolment were recorded. The severity of illness
was also assessed by vital signs, the Simplified Acute Physio-
logic Score II and the SOFA score. Finally, interventions
including the volume of fluid infusion during the previous 24
hours, the type and doses of vasopressors, and the mechani-
cal ventilation conditions were recorded.
Laboratory variables
Haematological and biochemical analysis, arterial lactate and
blood gases (allowing the determination of the PaO2/FiO2
ratio), blood cultures and cultures of specimen drawn from the
site of infection were carried out systematically. Thyroid func-
tion was assessed by triiodothyronine, thyroxine, and thyroid
stimulating hormone. The analytical methods used to assess
all laboratory variables were the routine methods performed in
each hospital. These methods are standardized according to
French quality guidelines in medical biology.
Follow-up
Patients were followed up for 1 year after randomization or
until death, depending on which occurred first. The following
variables were collected on days 2, 3, 4, 7, 10 and 14 after
randomization: vital signs, SOFA score, standard laboratory
tests, PaO2/FiO2 ratio, and interventions. Thyroid function was
assessed on day 7 and on day 14. Cultures of specimens
drawn from any new site of infection were performed through-
out the ICU stay. The occurrence of nosocomial pneumonia
and the need for dialysis was noted throughout the ICU stay.
In addition, the patient's status at ICU discharge, at hospital
discharge and 1 year after randomization was recorded.
Efficacy endpoints
The primary endpoint was the time to vasopressor therapy
withdrawal during the ICU stay. Secondary endpoints were
the duration of mechanical ventilation, the ICU and hospital
lengths of stay, and the mortality rates at ICU, at hospital dis-
charge, and at 7, 14, 28 and 180 days and 1 year after
randomization.
Safety endpoints
The following adverse events that could potentially be related
to selenium toxicity were closely monitored: refractory shock,
cardiac insufficiency, acute respiratory distress syndrome,
hepatitis cytolysis, epilepsy, polyradiculonevritis, bleeding or
coagulation disorders, and worsening of organ failure [7,21-
23,25].
All serious adverse events were reported by investigators and
were transmitted to the regulatory authorities according to the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (Revision of the ICH Guideline on Clinical Safety Data
Management – Data Elements For Transmission of Individual
Case Safety Reports, E2B(R3), current step 2, 12 May 2005).
All serious adverse events were blindly analysed and the
degree of suspected relatedness of selenium to event(s) was
assessed.
Sample size and statistical analysis
This phase II study arbitrarily planned to include 60 patients
(30 in each group) in order to assess the opportunity of a
larger phase III trial. Making the hypothesis that the percentage
of patients free of catecholamine at 10 days (end of study
treatment) would be 60%, the sample size would have allowed
the detection of an absolute increase of 25% of this percent-
age of patients in a two-sided test performed with a type I error
of 5% and a power of 80%.
Statistical analysis was performed with SAS statistical soft-
ware (V9.1; SAS Institute, Cary, NC, USA). Data are pre-
sented as the mean ± standard deviation for continuous
variables unless otherwise noted, and as numbers with corre-
sponding percentages for qualitative variables. Comparisons
between groups were performed using the Student t test or
Wilcoxon rank sum test as appropriate for continuous varia-
bles, and using the chi-square test, the Fisher exact test or the
Cochrane–Mantel–Haenzel test as appropriate for categorical
variables. Cumulative event curves were constructed by the
Kaplan–Meier method and the effect of treatment was ana-
lysed using the log-rank test. All analyses were performed
according to the intent-to-treat principle (all randomized
patients were analysed according to the treatment group in
which they were assigned). All reported P  values are two
sided, and P < 0.05 was considered significant.
Results
Between 8 February 2002 and 12 March 2004, a total of 60
patients were randomized (29 in the placebo group and 31 in
the selenium group). All patients were followed up for the
entire study period and were analysed as shown in Figure 1
(an intention-to-treat analysis).
Characteristics of patients at inclusion
There was no significant difference between the two patient
groups for the general characteristics at randomization except
for the admission category, which showed a greater propor-
tion of patients of medical origin in the selenium group (Table
1). The majority of the patients were included within 48 hours
after ICU admission, with no significant difference between
groups (79% and 90% in the placebo and selenium groups,
respectively; P = 0.405).
The severity of illness at randomization was similar between
the two groups except that the blood haemoglobin concentra-
tion was higher in the selenium group (Table 2). The origin ofCritical Care    Vol 11 No 4    Forceville et al.
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sepsis was mainly pulmonary, with a significantly higher rate of
pneumonia in the selenium group, followed by peritoneal sep-
sis in the two groups (Table 3). In the selenium group, purely
pulmonary infection was significantly twice more frequent and
multisite infection was significantly four times less observed
compared with the placebo group. The type of organism
involved did not significantly differ between the two groups
(Table 3).
Efficacy
There was no significant difference between the two groups
for time to vasopressor therapy withdrawal (Figure 2). The
median time to vasopressor therapy withdrawal was 7 days in
both groups (95% confidence interval = 5–8 and 6–9 in the
placebo and selenium groups, respectively; log-rank, P  =
0.713). The vasopressor-free rate on day 10 was 86% and
82% in the placebo and selenium groups, respectively (P =
0.775). The median (interquartile range) duration of mechani-
cal ventilation was 14 (8–23) days in the placebo group and
was 19 (7–34) days in the selenium group, respectively (P =
0.762). The median (interquartile range) ICU and hospital
lengths of stay did not differ between the placebo and sele-
nium groups (18 (10–31) days versus 21 (7–40) days,
respectively, for the ICU length of stay; P = 0.836; and 33
(11–51) days versus 25 (7–68) days, respectively, for the hos-
pital length of stay; P = 0.704). The mortality rates at ICU dis-
charge, at hospital discharge, and at 7, 14, 28, and 180 days
and 1 year after randomization were also similar in the two
groups (Figure 3).
The SOFA score did not differ between groups during the 14
days of follow-up, and neither did the PaO2/FiO2 ratio and the
triiodothyronine, thyroxine, and thyroid stimulating hormone
levels (data not shown). The percentages of patients who had
at least one nosocomial pneumonia event during the ICU stay
were similar in the two groups (45% versus 55% for the pla-
cebo and selenium groups, respectively; P = 0.438), and the
number of days free of dialysis were also similar in the two
groups (26 ± 49 days versus 37 ± 55 days in the placebo and
selenium groups, respectively; P = 0.303).
Safety
At least one serious adverse event occurred in 62% and in
81% of the patients in the placebo and selenium groups,
respectively (P = 0.111). The type of adverse event did not
significantly differ between the two groups (Table 4), even
though there was a trend to a higher rate of multiorgan failure
in the selenium group (P  = 0.09). None of these adverse
events were classified as 'possibly' or 'probably' related to the
study treatment.
Discussion
In our study, the administration of 4,000 μg selenium, as a con-
tinuous infusion of sodium selenite, followed by 1,000 μg
selenium per day during the nine following days was safe, but
did not have any effect on the weaning of catecholamines.
Moreover, there were no positive effects on the duration of
mechanical ventilation, the ICU and hospital lengths of stay,
and the mortality rates, as well as on the occurrence of noso-
comial pneumonia and the need for renal replacement.
Differences between groups were found among few baseline
characteristics due to a failure of randomization. For example,
there was a higher rate of pneumonia in the treated group. The
results of the study were far from significance, however, and it
is probable that these imbalances do not impact the
conclusions.
Our results do not agree with previous findings in sepsis trials.
This is all the more surprising since we specifically included
severe septic shock patients who were supposed to be the
most responsive to selenium administration [35-37]. The fact
that we did not observe any reduction of the hospital length of
stay and infection rates, especially for nosocomial pneumonia,
did not observe any effect on organ failure assessment, partic-
ularly renal failure, and observed no decrease in mortality also
contrasts with the results of previous studies [35,36,38-43].
This absence of a beneficial effect of selenium treatment could
theoretically be related to the small size of the study allowing
conclusions only on the main endpoint. One must, however,
underline that there was no trend to efficacy. Discrepancies
could also be explained by differences in the type and severity
of patients and/or in the therapeutic schedule. For example,
mainly burn patients and trauma patients were included in the
studies of Berger and colleagues instead of septic shock
patients [38-41]. Selenium was administered as sodium
selenite but daily doses were less than 500 μg, matched to
Figure 1
The participant flow diagram The participant flow diagram. *Use of data was permitted by the 
patient.Available online http://ccforum.com/content/11/4/R73
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substitute for losses, and they were administered in associa-
tion with multi-antioxidant trace elements and sometimes with
antioxidant multivitamins. The studies of Angstwurm and col-
leagues, of Kuklinski and colleagues, and of Zimmerman and
colleagues, and the Selenium in Intensive Care studies, were
respectively performed in patients with severe systemic inflam-
matory response syndrome, with acute pancreatitis or with
sepsis syndrome instead of in patients with severe septic
shock [35,36,42,43]. In these studies, doses ranged from 500
to 2,000 μg on the first day and the durations of intravenous
administration were 9 days, 6 days, 28 days and 14 days,
respectively, all with decreasing doses.
Another possible explanation for the absence of an effect
could be an incipient toxicity of sodium selenite counterbal-
ancing the moderate beneficial effect related to selenium infu-
sion [44]. Indeed, it is well known in nutrition that trace
element supplementation, particularly for selenium, is charac-
terized by a dose–response curve with a plateau that is fol-
lowed by toxicity if doses are increased [28,45,46]. These
Table 1
General characteristics at randomisation
Characteristic Placebo group (n = 29) Selenium group (n = 31) P value
Age (years) 69 ± 12 66 ± 14 0.354
Male/female (n) 18/11 20/11 0.844
McCabe classification
No disease 3 (10) 4 (13) 0.713
Nonfatal disease 16 (55) 14 (45)
Ultimately fatal disease 10 (35) 13 (42)
Rapidly fatal diseases 0 (0) 0 (0)
Level of activity limitationa
A 2 (7) 5 (16) 0.548
B 15 (52) 10 (32)
C 7 (24) 6 (20)
D 5 (17) 10 (32)
Prior or pre-existing disease
Hypertension 14 (48) 10 (32) 0.206
Coronary artery disease 6 (21) 2 (7) 0.140
Congestive heat failure 2 (7) 6 (19) 0.257
Chronic pulmonary disease 7 (24) 9 (29) 0.668
Diabetes 5 (17) 7 (23) 0.605
Liver disease 3 (10) 0 (0) 0.107
Cancer 4 (14) 7 (23) 0.379
Length of hospital stay before enrolment
<14 days 24 (83) 29 (93) 0.064
14–28 days 4 (14) 0 (0)
≥ 28 days 1 (3) 2 (7)
Admission category
Medical 18 (62) 29 (94) 0.003
Emergency surgery 10 (35) 2 (6)
Elective surgery 1 (3) 0 (0)
Data presented as the mean ± standard deviation for quantitative variables and n (%) for qualitative variables. aLevels of activity limitation defined 
as follows: A, prior good health; B, mild to moderate limitation of activity because of chronic medical problem; C, chronic disease producing 
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Table 2
Severity of illness at randomisation
Variable Placebo group (n = 29) Selenium group (n = 31) P value
Temperature (°C) 37.9 ± 1.3 37.9 ± 1.1 0.778
Mean arterial pressure (mmHg) 61 ± 22 64 ± 17 0.343
Heart rate (beats/min) 121 ± 38 121 ± 28 0.938
Simplified Acute Physiologic Score II at inclusion 62 ± 13 61 ± 20 0.824
Sequential Organ Failure Assessment score at inclusion 12 ± 3 11 ± 3 0.161
Haemoglobin (g/dl) 9.9 ± 2.0 11.3 ± 1.9 0.005
Leucocytes (x103/μl) 14.0 ± 12.2 15.7 ± 9.1 0.243
Platelets (x103/μl) 210 ± 163 253 ± 156 0.237
Arterial lactate (mmol/l) 4.2 ± 3.9 3.8 ± 2.4 0.600
PaO2/FiO2 (kPa) 21.7 ± 13.4 19.8 ± 14.7 0.329
Fluid infusion (l)a 3.3 ± 2.4 2.8 ± 1.9 0.436
Vasopressor therapy at randomizationb
Dopamine 21 (72) 19 (61) 0.361
Dobutamine 8 (28) 7 (23) 0.655
Epinephrine 12 (41) 14 (45) 0.768
Norepinephrine 19 (66) 13 (42) 0.067
Data presented as the mean ± standard deviation for quantitative variables and n (%) for qualitative variables. aAmount of fluid infused during the 
previous 24 hours. bDopamine at any dose; dobutamine, epinephrine and norpinephrine at doses corresponding to the inclusion criteria.
Table 3
Origin of sepsis and type of organism involved
Characteristic Placebo group (n = 29) Selenium group (n = 31)
Site of infection
Lung only 9 (31) 19 (61)a
Abdomen only 5 (17) 2 (6)
Urinary tract only 1 (3) 0 (0)
Other (one site only)b 3 (10) 7 (23)
More than one site 11 (38) 3 (10)c
At least one positive blood culture 12 (41) 8 (26)
Type of positive culture (any site)
Purely Gram-positive 9 (31) 4 (13)
Purely Gram-negative 10 (34) 5 (16)
Anaerobes only 2 (7) 0 (0)
Mycobacterium 0 (0) 1 (3)
Mixed 7 (24) 11 (35)
Data presented as n (%). aP = 0.019. bOther sites included bone, catheter-related infection, septicaemia, central nervous system or 
oropharyngeal infections. cP = 0.010.Available online http://ccforum.com/content/11/4/R73
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data, when considered together, may therefore suggest that
the dose used in the present trial was beyond the optimal dose
supporting immune defence.
It is important to note that, in the studies of Kuklinski and col-
leagues and of Zimmerman and colleagues, and in the Sele-
nium in Intensive Care studies – which respectively showed
90%, 35% and 10% reductions of mortality rates – sodium
selenite was administered using a bolus injection for the first
administration. Moreover, one study used a similar scheme of
continuous administration as the present study [47], in which
administration was performed on 70 pancreatitis patients and
the first dose of sodium selenite was 2 mg followed by 4 days
at 300 μg/day. Their study failed to find any benefit, especially
on mortality. To reduce the binding of NF-κB to DNA with
selenite in vivo, therefore, a bolus administration is perhaps
needed to reach high selenite blood concentrations that could
not be attained by continuous administration [32,33,46].
Experimental animal studies are required to answer these
questions.
We did not observe any of the predefined adverse events
related to selenium as sodium selenite, despite using higher
doses than those usually used in experimental studies (250–
Figure 2
Time to vasopressor therapy withdrawal Time to vasopressor therapy withdrawal.
Figure 3
One year survival distribution One year survival distribution. Mortality rates were 45% vs. 45% (p = 0.59), on day 28; 59% vs. 68% (p = 0.32) at 6 month; and 66% vs. 71% (p = 
0.43) at one year in the placebo and selenium groups, respectively.Critical Care    Vol 11 No 4    Forceville et al.
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1,000 μg/day selenium) [8] that are far above previous recom-
mendations (less than 700 μg/day selenium) [23,29-31].
Since a unique ingestion of 4 mg selenium is considered non-
toxic in healthy man [22], we chose to administer sodium
selenite corresponding to 4,000 μg selenium in septic shock
patients using a continuous administration, rather than a bolus,
to limit the risk of toxicity. This dose was followed by a 9-day
administration of selenium as sodium selenite for antioxidant
purposes. At these doses, the occurrence of side effects that
could be related to the pro-oxidative properties of selenite
were similar in the two groups, such as an increase in catecho-
lamine requirement, cardiac insufficiency, acute respiratory
distress syndrome, hepatitis cytolysis, epilepsy, polyradicu-
lonevritis, and bleeding or coagulation disorders [7,21-
23,25,44].
Conclusion
In the present study, a continuous infusion of high doses of
sodium selenite corresponding to 4 mg selenium the first day
and 1 mg/day for the nine following days had no obvious tox-
icity but did not improve the clinical outcome in septic shock
patients. The results of this nonpositive study may be related
to the small sample size, to the inadequate dose and/or modal-
ities of administration, or to an incipient toxicity of selenite
counterbalancing a moderate beneficial effect. These results
may paradoxically highlight interest in a selenite blood peak
concentration at an early stage of sepsis. Considering that a
dose above 500–800 μg/day selenium should not be admin-
istered in routine practice in ICU patients outside experimental
situations, and considering the potential interest of bolus
administration, septic shock animal studies are first needed to
test the efficacy of this approach as well as the mechanism of
its action.
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